Pharmacogenomics

Week of 6 October 2026

6 articles

Geno'X Veille — genox-veille.fr

Key takeaways this week

►CYP2C19 — rapid testing in stroke/TIA: result before discharge in 97% of patients and ticagrelor in 87% of intermediate/poor metabolizers.
►Hypertension — randomised trial (n = 2,702): greater blood pressure reduction at 4 weeks under pharmacogenomics-guided treatment.
►VKORC1 — rs9934438 misclassifies 2 of 939 patients relative to rs9923231: prefer the reference variant.
►CYP2D6 — phenotype associated with persistent opioid use after spine surgery (n = 3,820), replication needed.
►SLC47A1 — rs2289669 GG associated with a greater creatinine rise under abemaciclib; pre-treatment cystatin C advised.

Category:

Filters··Min. score

6 articles of 6

Sort

Implementation of Rapid CYP2C19 Genotyping to Guide Antiplatelet Therapy for Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack.

Secondary prevention of ischemic stroke and TIA on antiplatelet therapy

CardiologyDose recommendation

Clin Pharmacol Ther 2026· OctRead

Essential hypertension

Pharmacogenomics-guided therapy for essential hypertension: a multi-center randomized controlled open-label trial.

Essential hypertension

Front Cardiovasc Med 2026· SepRead

Limitations of VKORC1 rs9934438 as a Surrogate Marker for Vitamin K Antagonist Dose Adjustment.

Vitamin K antagonist dosing

Basic Clin Pharmacol Toxicol 2026· NovRead

CYP2D6 Metabolizer Phenotype and New Persistent Opioid Use After Spine Surgery.

New persistent opioid use after spine surgery

Global Spine J 2026· SepRead

Creatinine-Cystatin C Discrepancy and Renal Transporter Polymorphisms in Japanese Patients with Breast Cancer Receiving Abemaciclib.

Serum creatinine elevation under abemaciclib in breast cancer

Clin Pharmacol Ther 2026· SepRead

Association of CYP2C19 genetic polymorphisms with dyslipidemia and ischemic cerebrovascular disease in the mongolian population: A case-control study.

Ischemic cerebrovascular disease and dyslipidemia, Mongolian population

Medicine (Baltimore) 2026· OctRead

References and sources

CYP2C19 — Secondary prevention of ischemic stroke and TIA on antiplatelet therapy. Clin Pharmacol Ther 2026. PMID 42820662. Score 8/10. https://pubmed.ncbi.nlm.nih.gov/42820662/
Essential hypertension. Front Cardiovasc Med 2026. PMID 42827937. Score 7/10. https://pubmed.ncbi.nlm.nih.gov/42827937/
VKORC1 — Vitamin K antagonist dosing. Basic Clin Pharmacol Toxicol 2026. PMID 42823629. Score 5/10. https://pubmed.ncbi.nlm.nih.gov/42823629/
CYP2D6 — New persistent opioid use after spine surgery. Global Spine J 2026. PMID 42813508. Score 5/10. https://pubmed.ncbi.nlm.nih.gov/42813508/
SLC47A1 — Serum creatinine elevation under abemaciclib in breast cancer. Clin Pharmacol Ther 2026. PMID 42773505. Score 4/10. https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.70490?af=R
CYP2C19 — Ischemic cerebrovascular disease and dyslipidemia, Mongolian population. Medicine (Baltimore) 2026. PMID 42826334. Score 4/10. https://pubmed.ncbi.nlm.nih.gov/42826334/

29 September 2026